AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05777811 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free gingival graft
Description: A partial-thickness flap is elevated (using a blade #15c) with horizontal incisions at the cemento-enamel junction (CEJ) level of the adjacent teeth. Then, two vertical incisions extending to the apical are made from the two ends of the horizontal incision. The epithelium in the framed region is removed with a scalpel, and the underlying connective tissue is exposed. To achieve the best vascularization of the free gingival graft from the recipient site, bed preparation is completed with a split-thickness horizontal incision that joins the vertical incisions in the apical region. The free gingival graft is stabilized using interrupted sutures and a sling suture.
Study NCT05863364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose of Rifaximin
Description: The patients in group B were given rifaximin with the dose of 600mg/d (600mg, qd) for 24 weeks
Study NCT05863364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional dose of Rifaximin
Description: the patients in group C were delivered 1200mg/d (600mg, bid) for 24 weeks
Study NCT05615350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meals served during breakfast with a wide range of different food textures
Description: Ad libitum portions of twelve different meals with a wide range of food textures served during breakfast at the eating behaviour lab
Study NCT05615350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Meals served during lunch with a wide range of different food textures
Description: Ad libitum portions of twelve different meals with a wide range of food textures served during lunch at the eating behaviour lab
Study NCT06356597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab with Fruquintinib, Metronidazole
Description: Metronidazole tablets: One administration cycle is every 6 weeks, and metronidazole tablets are given orally on the 1st to 7th day of each cycle. The medication method is two tablets three times one day.~Teralizumab: Every 3 weeks is a dosing cycle, with 200mg of Teralizumab administered intravenously on the first day of each cycle.
Study NCT05783323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Larotrectinib monotherapy
Description: Patients will receive larotrectinib monotherapy for 6 months at the FDA-approved dose.
Study NCT05783323 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 131I therapy
Description: Patients will receive 131I therapy after 6 months of larotrectinib.
Study NCT06359535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HSK21542
Description: This study is an economic study and does not interfere with patients' medical treatment.
Study NCT06359535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05206604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07295324
Description: Ointment
Study NCT05206604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07259955
Description: Cream
Study NCT06116032 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Methylation Cytometry
Description: Assessment of the ability of Methylation Cytometry in pre-treatment peripheral blood and in repeated measures over the duration of treatment to predict treatment response or occurrence of adverse events.
Study NCT04509011 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluobeam® LX
Description: Fluobeam®-LX is used to identify and evaluate parathyroid glands using auto-fluorescence during thyroid surgery.
Study NCT06270394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-Fibroblast activation protein inhibitor
Description: Fibroblast activation protein (FAP), a type II transmembrane serine protease with dipeptidyl peptidase and endopeptidase activities. FAP is a specific surface marker for activated fibroblasts in the mesenchyme of tumors, which account for 90% of the stroma of epithelial neoplasms. FAP inhibitors (FAPIs) can specifically target and bind to FAP. These inhibitors that are radiolabeled with gallium 68 (68Ga-FAPIs) can be probes for visualization of the FAP tumor stroma. Previous studies have demonstrated that 68Ga-FAPI-04 is not dependent on blood glucose levels, has an equal or better tumor-to-background ratio, and clearly visualizes primary tumors and their metastatic foci. In addition, previous studies on 68Ga-FAPI-04 have focused on PET/CT and the efficacy of PET/MR with FAPI for postoperative evaluation of GI tumors remains to be clarified.
Study NCT04307355 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcu O2®
Description: Participants randomized into study active group will be provided with a Transcu O2® at their surgical site and followed for 4 weeks.
Study NCT05410795 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Magnetic resonance imaging
Description: Enrolled subjects will be examined with MRI of pancreas, and the volume, length and thickness of coronal plane of pancreas will be measured by software.
Study NCT05109195 — intervention group
Intervention type: OTHER
Intervention: Standard of Care (SOC)
Description: Participants will not receive any intervention as a part of this study. Participants will receive SOC treatment.
Study NCT05520450 — intervention group
Intervention type: BEHAVIORAL
Intervention: Telematic support group
Description: The participation of each patient in the study has been established for 4 months; the first and last months correspond to the evaluation phase, the remaining two months are for the intervention. A total of 7 group sessions of 90 minutes duration and weekly frequency are scheduled, carried out via telematics and conducted by an emotional well-being professional, a nurse and a social worker. In this context, it is guaranteed that patients will receive the care, visits and treatments usually used for people who have presented their clinical situation. The only difference between participating in the intervention and not participating in the intervention is the participation in a telematic support group and some additional assessments, i.e. not routinely carried out, which are part of this project. The intervention will be carried out in a group format, with a maximum of 12 patients per session.
Study NCT05406570 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standardized ventilation
Description: Patient will be ventilated with tidal volume 6 mL/kg predicted body weight (PBW) and positive end-expiratory pressure (PEEP) according to the PEEP-FiO2 table of the ARMA trial. A CT scan will be performed with this ventilatory setting and the patients will be switched to the other group
Study NCT05406570 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standardized ventilation
Description: Patient will be ventilated with tidal volume 6 mL/kg predicted body weight (PBW) and positive end-expiratory pressure (PEEP) according to the PEEP-FiO2 table of the ARMA trial. A CT scan will be performed with this ventilatory setting and the patients will be switched to the other group
Study NCT05406570 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Personalized ventilation
Description: Patient will be ventilated with PEEP according to the PEEP-FiO2 table of the ARMA trial. Tidal volume will be selected as the tidal volume minimizing cardiopulmonary interactions as assessed on arterial pressure tracing, during a VT trial. A CT scan will be performed with this ventilatory setting and the patients will be switched to the other group.
Study NCT05406570 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Personalized ventilation
Description: Patient will be ventilated with PEEP according to the PEEP-FiO2 table of the ARMA trial. Tidal volume will be selected as the tidal volume minimizing cardiopulmonary interactions as assessed on arterial pressure tracing, during a VT trial. A CT scan will be performed with this ventilatory setting and the patients will be switched to the other group.
Study NCT05847543 — intervention group
Intervention type: OTHER
Intervention: Stool diaper data and sample collection
Description: Stool diaper data and sample collection
Study NCT05424315 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg
Description: 10mg Tab once daily
Study NCT05424315 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glucose Tab
Description: Placebo Oral Tablet
Study NCT06267508 — intervention group
Intervention type: PROCEDURE
Intervention: Maternal HIV viral load testing at delivery for VHT risk assessment
Description: Maternal HIV viral load testing will be performed for all mothers enrolled in the study at delivery. Results will be used along with WHO-defined clinical criteria to determine risk status for VHT. The intervention also includes personnel to support the additional testing volume and management of high-risk cases and eHealth solutions for communication of test results between health facilities.
Study NCT04745806 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActiGraft
Description: Whole blood clot (WBC) gel
Study NCT05026619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information about age-related fertility
Description: The following information is provided:~Age and fertility IVF success rates and side effects
Study NCT05026619 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Information about policy initiatives
Description: The following information is provided:~Assisted reproductive technology treatment subsidies Other fertility-related policies
Study NCT05026619 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Information about diabetes
Description: The following information is provided:~Diabetes risk factors and treatment Diabetes-related policies
Study NCT04504136 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serial Biopsy
Description: During the initial colonoscopy, 16-20 biopsies will be collected in addition to standard of care biopsies, and biopsy sites will be tattoed. Patients will return for a follow-up colonoscopy 4-35 days later. An additional 16-20 biopsies will be collected in a biopsy of the biopsy approach.
Study NCT06483828 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dental Anxiety Coping Module
Description: Dental tour where participants will be introduced to the dental clinic setting while Expressive Art Therapy, participants will engage with activity of making collage and finger painting.
Study NCT05051735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Paracetamol 500 mg
Study NCT05051735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05865535 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AV-380
Description: AV-380 is an immunoglobulin (Ig) G1 monoclonal antibody (mAb) intended to bind circulating human growth differentiation factor 15 (GDF-15), a cytokine involved in cancer-induced cachexia.
Study NCT06191133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Description: Fenofibrate is an FDA approved drug for cardiovascular indications and have decades of data supporting a favorable safety profile event with chronic use.
Study NCT05603351 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Men with a positive MR test are planned for a targeted MRI/US fusion and systematic prostate biopsy.~Men with a positive blood marker (either PSA, PSAD, or PHI) are planned for a systematic 12 core biopsy. Positive test results are PSA ≥ 3, integrated marker PSAD ≥ 0.15, and PHI ≥ 35.
Study NCT06628141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional support tool
Description: Nutritional support tool
Study NCT06627790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mouthwash preparation
Description: Participants will be divided into two groups Group A and Group B Both the groups will receive thorough scaling and root planing at required sites. Use of mouthwash preparation is adviced for 8 weeks and discontinue after for 4 weeks. The Visual analogue scale Hypersensitivity will be assessed via Visual Analogue Scale at 4, 8 and 12 week interval
Study NCT06627790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mouthwash preparation
Description: Participants will be divided into two groups Group A and Group B Both the groups will receive thorough scaling and root planing at required sites. Use of mouthwash preparation is adviced for 8 weeks and discontinue after for 4 weeks. The Visual analogue scale Hypersensitivity will be assessed via Visual Analogue Scale at 4, 8 and 12 week interval
Study NCT06223724 — intervention group
Intervention type: DEVICE
Intervention: STOP
Description: Software to measure impedance telemetry data
Study NCT06191133 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical Conization
Description: Cold knife conization or loop electrosurgical excision to remove cells and tissue in the cervix
Study NCT06191133 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Description: In a hysterectomy, the uterus, cervix, both ovaries, both fallopian tubes, and nearby tissue are removed.
Study NCT06191133 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Description: Chemotherapy uses anti cancer (cytotoxic) drugs to destroy cancer cells. The drugs circulate throughout the body in the bloodstream. Radiotherapy uses high energy waves similar to x-rays to kill cancer cells.
Study NCT06223724 — intervention group
Intervention type: DEVICE
Intervention: MAESTRO
Description: Software to measure impedance telemetry data
Study NCT06468514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: neural tensioning technique on radial nerve
Description: the neural group tensioning technique: The test should be performed in approximately 10° of shoulder abduction. The examiner extends the elbow 2 seconds just to the range where the patient notices tension but no pain and then the elbow is flexed. Three sets of 6-8 swings are performed with 1 minute rest in between.
Study NCT06468514 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sliding technique on radial nerve
Description: The mobilization maneuver begins by identifying the first resistance and the range of extension associated with pain. Maintaining elbow extension within the elastic region of resistance free of pain and/or paresthesia the examiner increases elbow extension and simultaneously allows the wrist to extend as necessary for the radial nerve branches in the forearm to glide proximally. The physical therapist then flexes the wrist while allowing the elbow to flex to cause the radial nerve excursion distally in the forearm.
Study NCT04934007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS Treatment
Description: 1 Hz rTMS
Study NCT04934007 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS Treatment
Description: 1 Hz rTMS
Study NCT06742099 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intercostal chest tube
Description: the use of chest tubes to drain malignant pleural effusion
Study NCT06742099 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Pleurodesis
Description: the injection of Talc in pleural space to induce inflammation reaction and produce pleurodesis
Study NCT05912335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical anesthetic
Description: The topical anesthetic, or topical formulation, was applied to the palatal mucosa for 2 minutes.
Study NCT05912335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical anesthetic
Description: The topical anesthetic, or topical formulation, was applied to the palatal mucosa for 2 minutes.
Study NCT05912335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical anesthetic
Description: The topical anesthetic, or topical formulation, was applied to the palatal mucosa for 2 minutes.
Study NCT05358639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib tablet
Description: Olaparib tablet will be administered alone for 14 days at a starting dose of 200 mg twice daily. Subsequently olaparib will be administered continuously over 28 days at a fixed dose and the dose of navitoclax will be escalated.
Study NCT05358639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navitoclax
Description: For navitoclax, a lead-in of 7 days at 150 mg PO will be used prior to dose escalation. The DLT period for dose levels above DL 3 will include the 14-day olaparib alone lead-in, the 7 days combination with navitoclax at 150 mg and the first 28 day cycle of the combination of olaparib and navitoclax cycle at the full dose level dosing (49 days).
Study NCT06390371 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spotlight AQ Survey platform
Description: A psychosocial assessment pinpointing the needs of patients divided into four domains: Therapy, Psychological, Social, Knowledge which is delivered to health care providers to guide their in clinic visits
Study NCT05656573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CART-PSMA cells
Description: This study consists of 2 parts:~Part A (Dose Escalation): The investigators are looking the highest dose of the study intervention that can be administered safely without severe or unmanageable side effects in participants that advanced prostate cancer.~Part B (Expansion Cohort): Participants will be treated at the respective dose (at or below the Maximum Tolerated Dose), as determined during Part A (Dose Escalation).~Up to 4 dosing cohorts, with up to 3 subjects enrolled in each cohort, will be explored as follows:~Cohort 1： CART-PSMA cells 1-3x10\^7/M\^2 (body surface area); Cohort 2： CART-PSMA cells 1-3x10\^8/M\^2 (body surface area); Cohort 3： Lymphodepletion chemotherapy + CART-PSMA cells 1-3x10\^7/M\^2 (body surface area); Cohort 4： Lymphodepletion chemotherapy + CART-PSMA cells 1-3x10\^8/M\^2 (body surface area).
Study NCT05256381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nanrilkefusp Alfa
Description: Subcutaneous (SC) injection.
Study NCT04938466 — intervention group
Intervention type: DRUG
Intervention: Long-Acting Growth Hormone (LAGH)
Description: Long-acting growth hormone (LAGH) treatment
Study NCT05256381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Intravenous (IV) infusion via peripheral or central venous line.
Study NCT05249348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PC14586
Description: An oral dose of PC14586 will be used in Arms A and B (Part 1) and a different dose will be used for Arms C and D and the Japanese cohort (Part 2).
Study NCT04755062 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Micronutrient-dense plant-rich Intervention
Description: The mNDPR dietary protocol is designed to be (1) micronutrient rich (i.e., high in plant-derived phytochemicals, antioxidants, vitamins, and minerals); (2) nutritionally adequate and diverse; (3) hormonally favorable, avoiding carbohydrates with a high glycemic index that could elevate levels of serum insulin and minimizing animal protein that may invoke an inflammatory response; and (4) encourage intake of regular meals, limited consumption of snacks, and an overnight fast of at least 12 hours. The calorie breakdown of the diet is derived from approximately: 30-60% vegetables, 10-40% beans/legumes, 10-40% fruit, 10-40% seeds/nuts, 20% whole grains, no more than 10% naturally raised and wild animal products, poultry, eggs, fish, dairy, oil and white potatoes.
Study NCT04755062 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Micronutrient-dense plant-rich Intervention
Description: The mNDPR dietary protocol is designed to be (1) micronutrient rich (i.e., high in plant-derived phytochemicals, antioxidants, vitamins, and minerals); (2) nutritionally adequate and diverse; (3) hormonally favorable, avoiding carbohydrates with a high glycemic index that could elevate levels of serum insulin and minimizing animal protein that may invoke an inflammatory response; and (4) encourage intake of regular meals, limited consumption of snacks, and an overnight fast of at least 12 hours. The calorie breakdown of the diet is derived from approximately: 30-60% vegetables, 10-40% beans/legumes, 10-40% fruit, 10-40% seeds/nuts, 20% whole grains, no more than 10% naturally raised and wild animal products, poultry, eggs, fish, dairy, oil and white potatoes.
Study NCT06284252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Gaming Simulation
Description: Two-dimensional virtual game simulations that can be played on computers will be developed using the recorded videos. Games will focus on physical examination of the heart, abdomen and respiratory system. The developed games will be played to the intervention group.
Study NCT05694546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker Post-Discharge Intervention
Description: Clients will be offered a community-based follow-up from a community health worker after hospital discharge.
Study NCT06449534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: It includes evaluation of the treatment process and past sessions. Simple shoulder biomechanics, function, and what caused the injury were explained to the patients. In order to increase patients' participation in treatment, it was emphasized what the treatment does and that the patient should cooperate in order to heal. During their treatment, patients are instructed to regulate their daily living activities, avoid overhead and repetitive movements of the arm, bags weighing more than 2-3 kg, etc. It was recommended not to carry them. Patients were informed about alternative sleeping positions.